Healthcare / Medical DistributionJakarta
$376.00
-2.00 (-0.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-165.0B · quality 33.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$566.9B
P/E
8.8x
↓EV/EBITDA
10.2x
↓ROE
11.3%
↑Gross Margin
23.5%
↓Debt/Equity
1.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.4%
FCF CAGR
—
FCF margin
-15.0%
FCF / Net income
-2.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.10T · net income $65.53B · FCF $-165.02B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1100.21B | $1100.21B | $977.49B | $696.30B | $753.57B |
| Net Income | $65.53B | $65.53B | $53.26B | $5.20B | $48.00B |
| EBITDA | $129.34B | $129.34B | $103.51B | $31.28B | $78.97B |
| EPS | — | — | 35.32 | 3.37 | 30.68 |
| Gross Margin | 23.5% | 23.5% | 21.5% | 19.5% | 21.1% |
| Operating Margin | 9.2% | 9.2% | 9.4% | 3.8% | 10.3% |
| Net Margin | 6.0% | 6.0% | 5.4% | 0.7% | 6.4% |
| Balance Sheet | |||||
| Debt/Equity | 1.45 | 1.45 | 1.21 | 0.52 | 0.33 |
| Current Ratio | 1.41 | 1.41 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-165.02B | $-165.02B | $-456.03B | $-72.95B | $-33.36B |
| Returns | |||||
| ROE | 11.3% | 11.3% | 10.4% | 1.1% | 9.9% |
| Valuation | |||||
| P/E | 8.83 | 8.83 | 11.49 | 209.20 | 33.90 |
| EV/EBITDA | 10.23 | 10.23 | 11.64 | 39.57 | 21.16 |
| P/B | 0.98 | 0.98 | 1.19 | 2.37 | 3.36 |
| Growth & Yield | |||||
| Revenue Growth | 12.6% | 12.6% | 40.4% | -7.6% | — |
| EPS Growth | — | — | 948.1% | -89.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.0%
Start / end P/E
n/dx → n/dx
EPS bridge
35.32 → n/d
Residual
-10.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.